188 related articles for article (PubMed ID: 7494510)
1. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Canpolat C; Pearson P; Robertson R; Jaffe N
Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Berrak SG; Pearson M; Berberoğlu S; Ilhan IE; Jaffe N
Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
[TBL] [Abstract][Full Text] [Related]
3. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
[TBL] [Abstract][Full Text] [Related]
4. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
5. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
7. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum(II).
Ruiz L; Gilden J; Jaffe N; Robertson R; Wang YM
Cancer Res; 1989 Feb; 49(3):742-4. PubMed ID: 2910492
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Goren MP; Wright RK; Pratt CB; Horowitz ME; Dodge RK; Viar MJ; Kovnar EH
Cancer Res; 1987 Mar; 47(5):1457-60. PubMed ID: 3815347
[TBL] [Abstract][Full Text] [Related]
10. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
12. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
13. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
Duan X; Jia SF; Koshkina N; Kleinerman ES
Cancer; 2006 Mar; 106(6):1382-8. PubMed ID: 16453328
[TBL] [Abstract][Full Text] [Related]
14. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
15. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
[TBL] [Abstract][Full Text] [Related]
18. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
19. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
20. High-dose ifosfamide in advanced osteosarcoma.
Marti C; Kroner T; Remagen W; Berchtold W; Cserhati M; Varini M
Cancer Treat Rep; 1985 Jan; 69(1):115-7. PubMed ID: 3855382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]